Last edited by Dugami
Monday, October 5, 2020 | History

4 edition of Development of iron chelators for clinical use found in the catalog.

Development of iron chelators for clinical use

Symposium on Development of Iron Chelators for Clinical Use (2nd 1980 San Francisco, Calif.)

Development of iron chelators for clinical use

proceedings of the Second Symposium on the Development of Iron Chelators for Clinical Use, held August 23-24, 1980 in San Francisco, California

by Symposium on Development of Iron Chelators for Clinical Use (2nd 1980 San Francisco, Calif.)

  • 65 Want to read
  • 33 Currently reading

Published by Elsevier/North Holland in New York, N.Y .
Written in English

    Subjects:
  • Iron chelates -- Therapeutic use -- Congresses.,
  • Chelation therapy -- Congresses.

  • Edition Notes

    Includes bibliographical references and index.

    Statementeditors, Arthur E. Martell, W. French Anderson, David G. Badman.
    ContributionsMartell, Arthur Earl, 1916-, Anderson, W. French, 1936-, Badman, David G.
    Classifications
    LC ClassificationsRM666.I82 S94 1980
    The Physical Object
    Paginationxviii, 311 p. :
    Number of Pages311
    ID Numbers
    Open LibraryOL4263979M
    ISBN 100444006508
    LC Control Number81009841
    OCLC/WorldCa7614849

    Iron Metabolism: From Molecular Mechanisms to Clinical Consequences 4th Edition, Kindle Edition Iron is indispensable for the growth, development and well-being of almost all living organisms. Biological systems from bacteria, fungi and plants to humans have evolved systems for the uptake, utilisation, storage and homeostasis of iron. Manufacturer: Wiley. The primary use of chelation has been transfusional iron overload. There is now an increasing body of evidence for the benefits of iron chelation in myelodysplasia, pre-stem cell transplantation, and potentially in the treatment of malignancies. Two new iron chelators are in development, one in phase 3 clinical trials and the other in.

    Ferrate(VI) is the inorganic anion with the chemical formula [FeO 4] 2−.It is photosensitive, contributes a pale violet colour to compounds and solutions containing it and is one of the strongest water-stable oxidising species gh it is classified as a weak base, concentrated solutions containing ferrate(VI) are corrosive and attack the skin and are only ChEBI: CHEBI One key clinical feature of iron chelators is the degree to which they are absorbed from the gastrointestinal tract. A clinically highly effective iron chelator such as desferrioxamine has the drawback of very poor absorption from the gastrointestinal tract (2).

    Iron chelation therapy, either subcutaneous or orally administered, has been used successfully in various clinical conditions. The removal of excess iron from various tissues, e.g., the liver spleen, heart, and the pituitary, in beta thalassemia patients, has become an essential therapy to prolong life. More recently, the use of deferiprone to chelate iron from various brain regions in Cited by: 1. @article{osti_, title = {Biomimetic Actinide Chelators: An Update on the Preclinical Development of the Orally Active Hydroxypyridonate Decorporation Agents 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO)}, author = {Durbin, Patricia W and Kullgren, Birgitta and Ebbe, Shirley N and Xu, Jide and Chang, Polly Y and Bunin, Deborah I and Blakely, Eleanor A and .


Share this book
You might also like
origins of Marxian thought.

origins of Marxian thought.

Loyalty, an ideal, a philosophy, a religion

Loyalty, an ideal, a philosophy, a religion

Current therapy of gastrointestinal disorders

Current therapy of gastrointestinal disorders

From the Indian Land

From the Indian Land

Lewis Wetzel

Lewis Wetzel

dynamics of urban property development

dynamics of urban property development

Wool carding.

Wool carding.

Self-identity and the I-thou relation

Self-identity and the I-thou relation

Result

Result

Characteristics of water spray nozzles

Characteristics of water spray nozzles

Development of iron chelators for clinical use by Symposium on Development of Iron Chelators for Clinical Use (2nd 1980 San Francisco, Calif.) Download PDF EPUB FB2

Representing an integration of basic and clinical sciences, this book focuses on new concepts in the design, synthesis, and testing of iron chelators for clinical application. It provides an overview of the pathophysiology of iron metabolism as it relates to the origins of iron-mediated tissue damage, and it clearly outlines successes and Cited by: Representing an integration of basic and clinical sciences, this book focuses on new concepts in the design, synthesis, and testing of iron chelators for clinical application.

It provides an overview of the pathophysiology of iron metabolism as it relates to the origins of iron-mediated tissue damage, and it clearly outlines successes and. ISBN: OCLC Number: Description: xiii, pages: illustrations ; 25 cm: Contents: Physiology and pathophysiology of iron metabolism: implications for iron chelation therapy in iron overload / P.

Ponka --Iron, oxidative damage and chelating agents / B. Halliwell --Iron chelation therapy in the treatment of iron overload / M.J.

Pippard. beyond the download The Development of Iron Chelators for Clinical Use CRC Press, One Bride Baby Included, Doreen Roberts, Jul 1,Fiction, pages Providing a fascinating tour of the culture, politics, religions, geography, economics, history, and peoples of. Get this from a library.

Development of iron chelators for clinical use: proceedings of a symposium, SeptemBethesda, Maryland. [W French Anderson; Merilyn C Hiller; National Institute of Arthritis, Metabolism, and Digestive Diseases (U.S.);]. from book Iron Physiology and Pathophysiology in Humans (pp) Clinical Use of Iron Chelators.

During the clinical development of the novel oral iron chelator deferasirox, LIC was. Iron-chelation therapy has largely focused on the treatment of iron overload in patients who receive multiple blood transfusions as supportive therapy for treatment of conditions such as β-thalassaemia, sickle cell disease and myelodysplasia [47,48].As discussed below, however, the potential spectrum of activity of iron chelators is much broader than by: Chemical and pharmacological properties of licensed chelators.

Three iron chelators are currently licensed for clinical use and their iron binding properties, routes of absorption, elimination and metabolism differ. These are summarized in Table 5.

Of note, the majority of information presented refers to prototype formulations of the by: 1. In book: Recent Advances in Pediatrics Development of Iron Chelators for Clinical Use.

January J. Neilands; Many microbes have developed the strategy of Author: Pankaj Abrol. Title: The Design and Development of Deferiprone (L1) and Other Iron Chelators for Clinical Use: Targeting Methods and Application Prospects VOLUME: 11 ISSUE: 16 Author(s):G.

Kontoghiorghes, K. Pattichis, K. Neocleous and A. Kolnagou Affiliation:Postgraduate ResearchInstitute of Science, Technology, Environment and Medicine, 3,Ammochostou Street, Cited by: Properties of therapeutic iron chelators.

Most natural siderophores are unsuitable for clinical use. Ideally, those used should be orally available and have the ability to cross biological membranes to target areas, such as the liver. In addition, they should not.

Clinical Guidelines on the Use of Iron Chelation in Children Receiving Regular Blood Transfusions This guideline covers the monitoring and management of children (receiving transfusions on Philip Isaacs ward) with transfusion-related iron overload, and is aimed at the paediatric and haematology members of the multi-disciplinary team.

These. Desferrioxamine B was approved for the clinic by the US Food and Drug Administration (FDA) in although it does not fit the ideal drug properties discussed above.

Desferrioxamine B is a hexadentate hydroxamate siderophore, binding iron tightly (pFe(III) at pH ) 7 in a ratio. Its large size and hydrophilicity reduces its ability to diffuse through membranes, and. Deferoxamine (Desferal, DFO) • First iron chelator in clinical use • Responsible for the major increase in survival in thalassemia major • Effective chelator with dose-dependent response • Removes liver and cardiac iron when given in adequate doses • Safe when used according to guidelines • Dose adjustment according to iron burden.

Richardson DR, Ponka P. Orally effective iron chelators for the treatment of iron overload disease: the case for a further look at pyridoxal isonicotinoyl hydrazone and its analogs. J Lab Clin Med. ;–2. PubMed Google ScholarCited by: 2.

Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim. Biophys. Acta (7),– ().

Recent review examining novel synthetic iron chelators for cancer ef, Medline, Google ScholarCited by: Abstract. The development of iron (Fe) chelators for clinical use remains an active research goal. Over the last thirty years desferrioxamine (DFO; Desferal R; Fig. 1) has been the drug of choice in the treatment of Fe overload disease.

I ’ 2 Despite its considerable success, the problems with this drug remain significant and much research has been invested to obtain alternative ligands Cited by: Iron chelators, therefore, may be required to remove iron in a highly selective manner whilst stabilising iron levels elsewhere even within the same cell.

Initial clinical trials [ 65 ] demonstrate that doses of deferiprone are well tolerated over the long term (6 months) with no stated propagation of a challenge to systemic iron by: @article{osti_, title = {Development of iron chelators for Cooley's anemia. Final report}, author = {Crosby, W.H.

and Green, R.}, abstractNote = {Iron chelators were screened in an iron-loaded rat model using selective radioiron probes. In all experiments, chelators D and F, in that order, induced significant loss of radioiron compared with controls. "The Development of Iron Chelators for Clinical Use" by Raymond J.

Bergeron, Gary M. Brittenham Symposia with The New York Academy of Sciences [ edit ] Since[6] the Foundation has partnered with the New York Academy of Sciences to present periodic symposia specifically focusing on the current status and future directions of clinical care.

Since iron can contribute to detrimental radical generating processes through the Fenton and Haber-Weiss reactions, it seems to be a reasonable approach to modulate iron-related pathways in inflammation.

In the human organism a counterregulatory reduction in iron availability is observed during inflammatory diseases. Under pathological conditions with reduced or Cited by: Spinach,whole grains such as buckwheat and amaranth, other vegetables such as chard and rhubarb, as well as beans and nuts, all contain significant levels of oxalic acid, which binds with iron, inhibiting its absorption.

Soy beans contain phytic acid, which also bind iron. Tea and coffee contain tannins, which block iron absorption. Clay and heavy metals also inhibit iron absorption.

Similarly controversial is the use of iron chelators for treating FA and other neurologic conditions. 14 the view of assessing by MRI the accessibility of iron accumulated in dentate nuclei of FA patients to a chelator in clinical use in iron overload at doses considered to be safe American Society of Hematology Education Program by: